Surgical strategies are tailored to biomarker-defined risks: focused parathyroidectomy for localized adenomas, subtotal resection for multigland disease (e.g., MEN1 carriers), or en-bloc resection for carcinoma-predictive signatures (CDC73 mutations). This evidence concerns the gene MEN1 and adenoma.